Giving healthcare companies and their stories the exposure they deserve.

Exicure (OTCQB:XCUR) expects to report data around the end of the third quarter of 2018 from two Phase 1 clinical trials, one in mild-to-moderate psoriasis and one in healthy volunteers with its lead spherical nucleic acid (SNA) drug candidates.

Closely-held Perimeter’s next-generation wide-field optical coherence tomography (OCT) technology for tumor tissue specimens has imaging resolution 10 times higher than ultrasound and 100 times higher than MRI.

ASLAN Pharmaceuticals (NASDAQ:ASLN; TPEx:6497) expects to report topline and interim data in the second half of 2018 from up to four clinical trials with its lead drug candidate, varlitinib, for the treatment of biliary tract (BTC) and gastric cancers, and with ASLAN003 for the treatment of acute myeloid leukemia (AML).

For the first time in a century, administration of epidural needles is being transformed with a smart device developed by closely-held Omeq Medical, which has completed a proof of concept (POC) preclinical study, is currently preparing for FDA submission, and expects to initiate first-in-human trials later this year.